Compare Novo Nordisk A/S (NVO) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs State Street Technology Select Sector SPDR ETF — how do they compare? Novo Nordisk A/S trades at $38.62 (market cap $165.31B), while State Street Technology Select Sector SPDR ETF trades at $198.92 (market cap $132.55B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays a 4.71% dividend while State Street Technology Select Sector SPDR ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and State Street Technology Select Sector SPDR ETF for 50 Days on average.
| NVO | XLK | |
|---|---|---|
Market Cap | $165.31B | $132.55B |
Volume | 11,432,838 | 9,063,135 |
Sector | Health | Sector/Thematic |
52-Week High | $63.98 | $202.00 |
52-Week Low | $35.29 | $127.49 |
Typical Hold Time | 116 Days | 50 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.64, up 0.99% with bearish technical signals despite strong fundamentals. The company maintains exceptional profitability with 35.35% net margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights pipeline developments including weight-loss drug advancements and a $4 billion licensing deal expansion.
While facing competitive pressure in obesity treatments, NVO's valuation remains attractive with a 9.66 P/E ratio. Analyst consensus is bullish with a $44.67 price target, representing 15.6% upside potential. Key risks include FDA regulatory delays and intensifying competition from Eli Lilly in the GLP-1 market.
XLK, the Technology Select Sector SPDR ETF, trades at $198.78, down 1.3% over the past day amid broader tech sector pressure. The technical outlook remains bullish based on moving averages, with neutral oscillators suggesting consolidation near the pivot point of $199. Recent news highlights AI-driven momentum in software stocks and ETF concentration concerns, while a future dividend of $0.22 is scheduled for September 2026.
The ETF's outlook is supported by strong AI investment themes and large-cap tech earnings resilience, but risks include interest rate sensitivity and high concentration in semiconductor holdings. Analyst sentiment is mixed, with some favoring alternative tech ETFs for better diversification. Key resistance lies at $201, with support at $196.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
